Novo Nordisk A/S
DKDKKNovo Nordisk A/S (US:NONOF) — Drug Manufacturers - General. Počet búrz, na ktorých sa obchodujú akcie spoločnosti: 4. Na tejto stránke — cena a graf, dividendy, najväčší akcionári a história počtu akcií.
O Spoločnosti
- Web
- novonordisk.com
- Vzťahy s Investormi
- novonordisk.com/investors/financial-calendar.html
- Sektor
- Healthcare · Drug Manufacturers - General
- Sídlo
- Bagsvaerd, Denmark
- Generálny Riaditeľ
- Maziar Mike Doustdar
- Zamestnanci
- 66 700
- Akcie v Obehu
- 3.34 mld.
- Voľne Obchodovateľné Akcie
- 3.17 mld.
- Trhová Kapitalizácia
- 1.08 bil. DKK
- Insideri
- 5.27%
- Inštitucionálni Investori
- 33.67%
- ISIN
- DK0060534915
- LEI
- 549300DAQ1CVT6CXN342
- P/E
- 8.5
- P/B
- 4.98
- Výplatný Pomer
- 50.5%
- FCF
- 59.0 mld. DKK
- Výplata / FCF
- 88%
- Dlh
- 143 mld. DKK2.0 r. FCF
- Dividendová Séria
- 25 r.
- Zisky, FCF a dividendy vyplatené — za 12 mesiacov do 31.12.2025 (najnovšia správa spoločnosti).
Popis
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Dividendy
Novo Nordisk A/S (NOVO-B) vypláca dividendy dvakrát ročne. Za rok (12 mesiacov až po poslednú oznámenú platbu): 11.7 DKK na akciu (platby: 2). To je približne 4.70% aktuálnej ceny akcie. Na základe histórie platieb sa ďalší dátum ex-dividendy očakáva okolo 07.01.2027. Roky neprerušených dividend: 25.
| Ex-Dátum | Výplata | Suma | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-08-18 | 3.7500 DKK | 1.3/3.9 % | polročný | CO:NOVO-B |
| 2026-03-27 | 2026-03-31 | 7.9500 DKK | 3.3/4.9 % | polročný | CO:NOVO-B |
| 2025-08-15 | 2025-08-19 | 3.7500 DKK | 1.2/3.6 % | polročný | CO:NOVO-B |
| 2025-03-28 | 2025-04-01 | 7.9000 DKK | 1.6/2.4 % | polročný | CO:NOVO-B |
| 2024-08-15 | 2024-08-19 | 3.5000 DKK | 0.4/1.1 % | polročný | CO:NOVO-B |
| 2024-03-22 | 2024-03-26 | 6.4000 DKK | 0.7/1.1 % | polročný | CO:NOVO-B |
| 2023-08-18 | — | 3.0000 DKK | 0.5/1.1 % | polročný | CO:NOVO-B |
| 2023-03-24 | — | 4.0750 DKK | 0.8/1.2 % | polročný | CO:NOVO-B |
| 2022-08-12 | — | 2.1250 DKK | 0.5/1.4 % | polročný | CO:NOVO-B |
| 2022-03-25 | — | 3.4500 DKK | 0.9/0.9 % | polročný | CO:NOVO-B |
Najväčší Držitelia
| Držiteľ | Podiel | Akcie | Dátum Správy |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.38% | 46.88 mil. | 2026-07-31 |
| EuroPacific Growth Fund-… | 1.07% | 36.2 mil. | 2026-06-30 |
| VANGUARD TAX-MANAGED FUN… | 0.92% | 31.13 mil. | 2026-06-30 |
| Capital World Growth & I… | 0.77% | 26.02 mil. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.71% | 24.13 mil. | 2026-08-31 |
| Income Fund of America | 0.52% | 17.78 mil. | 2026-07-31 |
| Dodge & Cox Funds-Dodge… | 0.39% | 13.1 mil. | 2026-06-30 |
| Fidelity Concord Street… | 0.37% | 12.52 mil. | 2026-07-31 |
| iShares Trust-iShares MS… | 0.34% | 11.48 mil. | 2026-08-31 |
| Capital Income Builder | 0.3% | 10.32 mil. | 2026-07-31 |
| Cygnus Capital Advisors,… | 0% | 78 800 | 2026-06-30 |
| Generali Investments Cee… | 0% | 27 399 | 2026-06-30 |
| Pacer Advisors, Inc. | 0% | 24 410 | 2026-06-30 |
| Atlas Capital Advisors I… | 0% | 5 218 | 2026-06-30 |
| Novo Holdings | — | — | — |
| Novo Nordisk Foundation | — | — | — |
